JP2019521111A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521111A5 JP2019521111A5 JP2018564345A JP2018564345A JP2019521111A5 JP 2019521111 A5 JP2019521111 A5 JP 2019521111A5 JP 2018564345 A JP2018564345 A JP 2018564345A JP 2018564345 A JP2018564345 A JP 2018564345A JP 2019521111 A5 JP2019521111 A5 JP 2019521111A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorophenoxy
- acetamide
- piperidin
- cancer
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 13
- 125000001153 fluoro group Chemical group F* 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 208000002780 macular degeneration Diseases 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 229940000425 combination drug Drugs 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000030090 Acute Disease Diseases 0.000 claims 3
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 claims 3
- 208000017667 Chronic Disease Diseases 0.000 claims 3
- 206010018404 Glucagonoma Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000006336 acinar cell carcinoma Diseases 0.000 claims 3
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 3
- 229940034982 antineoplastic agent Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- -1 chloro, bromo, iodo Chemical group 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 206010022498 insulinoma Diseases 0.000 claims 3
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- SDAFDLHADBQPAW-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[2-(4-chlorophenoxy)acetyl]piperidin-3-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CN(CCC2)C(COC2=CC=C(C=C2)Cl)=O)C=C1 SDAFDLHADBQPAW-UHFFFAOYSA-N 0.000 claims 2
- HUAGZYGFJWLPIW-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-(4-chlorophenoxy)propanoyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)C(CCOC2=CC=C(C=C2)Cl)=O)C=C1 HUAGZYGFJWLPIW-UHFFFAOYSA-N 0.000 claims 2
- IEFPRYVHZMCMLW-UHFFFAOYSA-N 4-[[2-(4-chlorophenoxy)acetyl]amino]-1-[3-(4-chlorophenoxy)propyl]piperidine-2-carboxylic acid Chemical compound ClC1=CC=C(OCC(=O)NC2CC(N(CC2)CCCOC2=CC=C(C=C2)Cl)C(=O)O)C=C1 IEFPRYVHZMCMLW-UHFFFAOYSA-N 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000012609 Cowden disease Diseases 0.000 claims 2
- 201000002847 Cowden syndrome Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- CLNAHCAPVFLXMG-UHFFFAOYSA-N 1-[2-(4-chlorophenoxy)acetyl]-N-[2-(4-chlorophenyl)ethyl]piperidine-4-carboxamide Chemical compound ClC1=CC=C(CCNC(=O)C2CCN(CC2)C(COC2=CC=C(C=C2)Cl)=O)C=C1 CLNAHCAPVFLXMG-UHFFFAOYSA-N 0.000 claims 1
- RQKPXUAOOBRMNF-SEJPIABJSA-N 2-(4-chlorophenoxy)-N-[(1R,5S)-8-[3-(4-chlorophenoxy)propyl]-8-azabicyclo[3.2.1]octan-3-yl]acetamide Chemical compound Clc1ccc(OCCCN2[C@H]3CC[C@@H]2CC(C3)NC(=O)COc2ccc(Cl)cc2)cc1 RQKPXUAOOBRMNF-SEJPIABJSA-N 0.000 claims 1
- LTKPWMPNGQGTKP-NHCUHLMSSA-N 2-(4-chlorophenoxy)-N-[1-[(1R,2R)-2-(4-chlorophenoxy)cyclopropanecarbonyl]piperidin-4-yl]acetamide Chemical compound Clc1ccc(OCC(=O)NC2CCN(CC2)C(=O)[C@@H]2C[C@H]2Oc2ccc(Cl)cc2)cc1 LTKPWMPNGQGTKP-NHCUHLMSSA-N 0.000 claims 1
- PYRNCZPMBRVYQL-HTAPYJJXSA-N 2-(4-chlorophenoxy)-N-[1-[(1R,2R)-2-[(4-chlorophenyl)methyl]cyclopropanecarbonyl]piperidin-4-yl]acetamide Chemical compound Clc1ccc(C[C@H]2C[C@H]2C(=O)N2CCC(CC2)NC(=O)COc2ccc(Cl)cc2)cc1 PYRNCZPMBRVYQL-HTAPYJJXSA-N 0.000 claims 1
- LTKPWMPNGQGTKP-RTWAWAEBSA-N 2-(4-chlorophenoxy)-N-[1-[(1R,2S)-2-(4-chlorophenoxy)cyclopropanecarbonyl]piperidin-4-yl]acetamide Chemical compound Clc1ccc(OCC(=O)NC2CCN(CC2)C(=O)[C@@H]2C[C@@H]2Oc2ccc(Cl)cc2)cc1 LTKPWMPNGQGTKP-RTWAWAEBSA-N 0.000 claims 1
- PYRNCZPMBRVYQL-JTSKRJEESA-N 2-(4-chlorophenoxy)-N-[1-[(1S,2R)-2-[(4-chlorophenyl)methyl]cyclopropanecarbonyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(C[C@@H]2[C@H](C2)C(=O)N2CCC(CC2)NC(COC2=CC=C(C=C2)Cl)=O)C=C1 PYRNCZPMBRVYQL-JTSKRJEESA-N 0.000 claims 1
- RXLGTJKEZRYHDT-LJQANCHMSA-N 2-(4-chlorophenoxy)-N-[1-[(2R)-3-(4-chlorophenoxy)-2-hydroxypropyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)C[C@H](COC2=CC=C(C=C2)Cl)O)C=C1 RXLGTJKEZRYHDT-LJQANCHMSA-N 0.000 claims 1
- RXLGTJKEZRYHDT-IBGZPJMESA-N 2-(4-chlorophenoxy)-N-[1-[(2S)-3-(4-chlorophenoxy)-2-hydroxypropyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)C[C@@H](COC2=CC=C(C=C2)Cl)O)C=C1 RXLGTJKEZRYHDT-IBGZPJMESA-N 0.000 claims 1
- ICRMSNZUVYLWPJ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[2-(3,4-dichlorophenoxy)ethyl]-3-fluoropiperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2C(CN(CC2)CCOC2=CC(=C(C=C2)Cl)Cl)F)C=C1 ICRMSNZUVYLWPJ-UHFFFAOYSA-N 0.000 claims 1
- SXOVROMRPMIVNU-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[2-(4-chlorophenoxy)acetyl]-3-fluoropiperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2C(CN(CC2)C(COC2=CC=C(C=C2)Cl)=O)F)C=C1 SXOVROMRPMIVNU-UHFFFAOYSA-N 0.000 claims 1
- IPZNJYJIAZIITG-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[2-(4-chlorophenoxy)acetyl]-3-methylpiperidin-4-yl]acetamide Chemical compound CC1CN(CCC1NC(=O)COc1ccc(Cl)cc1)C(=O)COc1ccc(Cl)cc1 IPZNJYJIAZIITG-UHFFFAOYSA-N 0.000 claims 1
- NZFYVDSLZDHEAB-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[2-(4-chlorophenoxy)acetyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)C(COC2=CC=C(C=C2)Cl)=O)C=C1 NZFYVDSLZDHEAB-UHFFFAOYSA-N 0.000 claims 1
- KCRGFNUBHMUFNZ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[2-(4-chlorophenoxy)ethyl]-3-fluoropiperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2C(CN(CC2)CCOC2=CC=C(C=C2)Cl)F)C=C1 KCRGFNUBHMUFNZ-UHFFFAOYSA-N 0.000 claims 1
- FBWNZQIMXQRATR-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[2-(4-chlorophenoxy)ethyl]-3-hydroxypiperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2C(CN(CC2)CCOC2=CC=C(C=C2)Cl)O)C=C1 FBWNZQIMXQRATR-UHFFFAOYSA-N 0.000 claims 1
- UAJNIHNUERTJJJ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[2-(4-chlorophenoxy)ethyl]-3-methylpiperidin-4-yl]acetamide Chemical compound CC1CN(CCOc2ccc(Cl)cc2)CCC1NC(=O)COc1ccc(Cl)cc1 UAJNIHNUERTJJJ-UHFFFAOYSA-N 0.000 claims 1
- CVIUEZUCLHVQFN-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[2-(4-chlorophenyl)cyclopropanecarbonyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)C(=O)C2C(C2)C2=CC=C(C=C2)Cl)C=C1 CVIUEZUCLHVQFN-UHFFFAOYSA-N 0.000 claims 1
- TWPTUJLPTQIUHG-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[2-[(5-chloro-1,2-thiazol-3-yl)oxy]ethyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC(=NS1)OCCN1CCC(CC1)NC(COC1=CC=C(C=C1)Cl)=O TWPTUJLPTQIUHG-UHFFFAOYSA-N 0.000 claims 1
- CUVFHRREYFDAJM-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-(3,4-dichlorophenoxy)propyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)CCCOC2=CC(=C(C=C2)Cl)Cl)C=C1 CUVFHRREYFDAJM-UHFFFAOYSA-N 0.000 claims 1
- FWYAKPGRSZBDDO-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-(4-chlorophenoxy)-2-fluoropropyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)CC(COC2=CC=C(C=C2)Cl)F)C=C1 FWYAKPGRSZBDDO-UHFFFAOYSA-N 0.000 claims 1
- RXLGTJKEZRYHDT-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-(4-chlorophenoxy)-2-hydroxypropyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)CC(COC2=CC=C(C=C2)Cl)O)C=C1 RXLGTJKEZRYHDT-UHFFFAOYSA-N 0.000 claims 1
- PTQVOFDUNFRWQS-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-(4-chlorophenoxy)-2-methoxypropyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)CC(COC2=CC=C(C=C2)Cl)OC)C=C1 PTQVOFDUNFRWQS-UHFFFAOYSA-N 0.000 claims 1
- WKDWVZMPHCVMQO-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-(4-chlorophenoxy)propyl]-2-oxopiperidin-4-yl]acetamide Chemical compound Clc1ccc(OCCCN2CCC(CC2=O)NC(=O)COc2ccc(Cl)cc2)cc1 WKDWVZMPHCVMQO-UHFFFAOYSA-N 0.000 claims 1
- VUWKMCVNOMZWBB-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-(4-chlorophenoxy)propyl]piperidin-4-yl]-N-methylacetamide Chemical compound ClC1=CC=C(OCC(=O)N(C)C2CCN(CC2)CCCOC2=CC=C(C=C2)Cl)C=C1 VUWKMCVNOMZWBB-UHFFFAOYSA-N 0.000 claims 1
- NCAZTXKTUWOOJG-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-(4-chlorophenoxy)propyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)CCCOC2=CC=C(C=C2)Cl)C=C1 NCAZTXKTUWOOJG-UHFFFAOYSA-N 0.000 claims 1
- IADNPAQXHWUHTH-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-(5-chloropyridin-2-yl)oxypropyl]piperidin-4-yl]acetamide Chemical compound Clc1ccc(OCC(=O)NC2CCN(CCCOc3ccc(Cl)cn3)CC2)cc1 IADNPAQXHWUHTH-UHFFFAOYSA-N 0.000 claims 1
- SRPCPZZPWPQOGO-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-(6-chloropyridin-3-yl)oxypropyl]piperidin-4-yl]acetamide Chemical compound Clc1ccc(OCC(=O)NC2CCN(CCCOc3ccc(Cl)nc3)CC2)cc1 SRPCPZZPWPQOGO-UHFFFAOYSA-N 0.000 claims 1
- RRPHUGRQHSANRS-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[3-[(5-chloro-1,2-thiazol-3-yl)oxy]propyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC(=NS1)OCCCN1CCC(CC1)NC(COC1=CC=C(C=C1)Cl)=O RRPHUGRQHSANRS-UHFFFAOYSA-N 0.000 claims 1
- RQTIPCTVVLRVMM-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[4-(4-chlorophenyl)butanoyl]-3-fluoropiperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2C(CN(CC2)C(CCCC2=CC=C(C=C2)Cl)=O)F)C=C1 RQTIPCTVVLRVMM-UHFFFAOYSA-N 0.000 claims 1
- LXLVCKWJABXRDF-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[1-[4-(4-chlorophenyl)butanoyl]piperidin-4-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)C(CCCC2=CC=C(C=C2)Cl)=O)C=C1 LXLVCKWJABXRDF-UHFFFAOYSA-N 0.000 claims 1
- YHGOTMIRLUEPJH-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[2-[1-[2-(4-chlorophenoxy)acetyl]piperidin-3-yl]ethyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NCCC2CN(CCC2)C(COC2=CC=C(C=C2)Cl)=O)C=C1 YHGOTMIRLUEPJH-UHFFFAOYSA-N 0.000 claims 1
- BFIZWKIJTFXDRR-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[2-[2-(4-chlorophenoxy)acetyl]-2-azabicyclo[2.2.1]heptan-5-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2C3CN(C(C2)C3)C(COC2=CC=C(C=C2)Cl)=O)C=C1 BFIZWKIJTFXDRR-UHFFFAOYSA-N 0.000 claims 1
- YBCDJKCLFFCWRJ-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[2-[3-(4-chlorophenoxy)-2-hydroxypropyl]-2-azabicyclo[2.2.1]heptan-5-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2C3CN(C(C2)C3)CC(COC2=CC=C(C=C2)Cl)O)C=C1 YBCDJKCLFFCWRJ-UHFFFAOYSA-N 0.000 claims 1
- JOAQZBRSUYTBKU-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[2-[3-(4-chlorophenoxy)propyl]-2-azabicyclo[2.2.1]heptan-5-yl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NC2C3CN(C(C2)C3)CCCOC2=CC=C(C=C2)Cl)C=C1 JOAQZBRSUYTBKU-UHFFFAOYSA-N 0.000 claims 1
- YORRSFUJEUOIAW-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[[1-[2-(4-chlorophenoxy)acetyl]piperidin-4-yl]methyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NCC2CCN(CC2)C(COC2=CC=C(C=C2)Cl)=O)C=C1 YORRSFUJEUOIAW-UHFFFAOYSA-N 0.000 claims 1
- AYUPSTWRQYVNSF-UHFFFAOYSA-N 2-(4-chlorophenoxy)-N-[[1-[3-(4-chlorophenoxy)propyl]piperidin-4-yl]methyl]acetamide Chemical compound ClC1=CC=C(OCC(=O)NCC2CCN(CC2)CCCOC2=CC=C(C=C2)Cl)C=C1 AYUPSTWRQYVNSF-UHFFFAOYSA-N 0.000 claims 1
- CUUAMCCAKPMQPY-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[1-[2-(4-chlorophenoxy)ethyl]piperidin-4-yl]acetamide Chemical compound C1=CC(Cl)=CC=C1OCCN1CCC(NC(=O)COC=2C=CC(Cl)=CC=2)CC1 CUUAMCCAKPMQPY-UHFFFAOYSA-N 0.000 claims 1
- JGMKZRVBSKAODJ-UHFFFAOYSA-N 2-[4-[[2-(4-chlorophenoxy)acetyl]amino]piperidin-1-yl]-4-(3,4-dichlorophenoxy)butanoic acid Chemical compound ClC1=CC=C(OCC(=O)NC2CCN(CC2)C(C(=O)O)CCOC2=CC(=C(C=C2)Cl)Cl)C=C1 JGMKZRVBSKAODJ-UHFFFAOYSA-N 0.000 claims 1
- BWECGZMXFKNDRC-UHFFFAOYSA-N 4-(4-chlorophenoxy)-2-[4-[[2-(3,4-dichlorophenoxy)acetyl]amino]piperidin-1-yl]butanoic acid Chemical compound ClC1=CC=C(OCCC(C(=O)O)N2CCC(CC2)NC(COC2=CC(=C(C=C2)Cl)Cl)=O)C=C1 BWECGZMXFKNDRC-UHFFFAOYSA-N 0.000 claims 1
- MUQWCCOAJINMHS-UHFFFAOYSA-N 4-(4-chlorophenoxy)-2-[4-[[2-(4-chlorophenoxy)acetyl]amino]piperidin-1-yl]butanoic acid Chemical compound ClC1=CC=C(OCCC(C(=O)O)N2CCC(CC2)NC(COC2=CC=C(C=C2)Cl)=O)C=C1 MUQWCCOAJINMHS-UHFFFAOYSA-N 0.000 claims 1
- KGIPMZXCKRJPQM-UHFFFAOYSA-N 4-[2-[(4-chlorophenoxy)methyl]imidazol-1-yl]-1-[3-(4-chlorophenoxy)propyl]piperidine Chemical compound ClC1=CC=C(OCC=2N(C=CN=2)C2CCN(CC2)CCCOC2=CC=C(C=C2)Cl)C=C1 KGIPMZXCKRJPQM-UHFFFAOYSA-N 0.000 claims 1
- QFDSCLWIILASNT-UHFFFAOYSA-N 6-chloro-N-[1-[3-(4-chlorophenoxy)propyl]piperidin-4-yl]-3,4-dihydro-2H-chromene-2-carboxamide Chemical compound ClC=1C=C2CCC(OC2=CC=1)C(=O)NC1CCN(CC1)CCCOC1=CC=C(C=C1)Cl QFDSCLWIILASNT-UHFFFAOYSA-N 0.000 claims 1
- OOWVALZPXYWWRL-UHFFFAOYSA-N 8-[2-(4-chlorophenoxy)acetyl]-3-[2-(4-chlorophenoxy)ethyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound ClC1=CC=C(OCC(=O)N2CCC3(CN(C(O3)=O)CCOC3=CC=C(C=C3)Cl)CC2)C=C1 OOWVALZPXYWWRL-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008263 Cervical dysplasia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000035984 Colonic Polyps Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000006402 Ductal Carcinoma Diseases 0.000 claims 1
- 208000019878 Eales disease Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 208000000265 Lobular Carcinoma Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 229940122255 Microtubule inhibitor Drugs 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- YAMSDJFJAKDUJU-UHFFFAOYSA-N N,1-bis[2-(4-chlorophenoxy)ethyl]piperidine-4-carboxamide Chemical compound ClC1=CC=C(OCCNC(=O)C2CCN(CC2)CCOC2=CC=C(C=C2)Cl)C=C1 YAMSDJFJAKDUJU-UHFFFAOYSA-N 0.000 claims 1
- KSFGBWYBEQYEOL-UHFFFAOYSA-N N-[1-[2-(4-chlorophenoxy)ethyl]-3-fluoropiperidin-4-yl]-2-(3,4-dichlorophenoxy)acetamide Chemical compound ClC1=CC=C(OCCN2CC(C(CC2)NC(COC2=CC(=C(C=C2)Cl)Cl)=O)F)C=C1 KSFGBWYBEQYEOL-UHFFFAOYSA-N 0.000 claims 1
- VEMJHNHRRFNXAM-UHFFFAOYSA-N N-[1-[3-(4-chlorophenoxy)propyl]piperidin-4-yl]-2-(2,4-dichlorophenoxy)acetamide Chemical compound ClC1=CC=C(OCCCN2CCC(CC2)NC(COC2=C(C=C(C=C2)Cl)Cl)=O)C=C1 VEMJHNHRRFNXAM-UHFFFAOYSA-N 0.000 claims 1
- GTJAJSDBDAEGAB-UHFFFAOYSA-N N-[1-[3-(4-chlorophenoxy)propyl]piperidin-4-yl]-2-(3,4-dichlorophenoxy)acetamide Chemical compound ClC1=CC=C(OCCCN2CCC(CC2)NC(COC2=CC(=C(C=C2)Cl)Cl)=O)C=C1 GTJAJSDBDAEGAB-UHFFFAOYSA-N 0.000 claims 1
- NOZTYYAWCZKPFX-UHFFFAOYSA-N N-[1-[3-(4-chlorophenoxy)propyl]piperidin-4-yl]-2-(4-cyclopropylphenoxy)acetamide Chemical compound ClC1=CC=C(OCCCN2CCC(CC2)NC(COC2=CC=C(C=C2)C2CC2)=O)C=C1 NOZTYYAWCZKPFX-UHFFFAOYSA-N 0.000 claims 1
- VTFMRDNMAFFPIU-UHFFFAOYSA-N N-[1-[3-(4-chlorophenoxy)propyl]piperidin-4-yl]-2-(5-chloropyridin-2-yl)oxyacetamide Chemical compound ClC1=CC=C(OCCCN2CCC(CC2)NC(COC2=NC=C(C=C2)Cl)=O)C=C1 VTFMRDNMAFFPIU-UHFFFAOYSA-N 0.000 claims 1
- ZOWIXMCYFHDLBA-UHFFFAOYSA-N N-[1-[3-(4-chlorophenoxy)propyl]piperidin-4-yl]-2-(6-chloropyridin-3-yl)oxyacetamide Chemical compound ClC1=CC=C(OCCCN2CCC(CC2)NC(COC=2C=NC(=CC=2)Cl)=O)C=C1 ZOWIXMCYFHDLBA-UHFFFAOYSA-N 0.000 claims 1
- OXLYQKMUWHBNTG-UHFFFAOYSA-N N-[1-[3-(4-chlorophenoxy)propyl]piperidin-4-yl]-2-[4-(difluoromethoxy)phenoxy]acetamide Chemical compound ClC1=CC=C(OCCCN2CCC(CC2)NC(COC2=CC=C(C=C2)OC(F)F)=O)C=C1 OXLYQKMUWHBNTG-UHFFFAOYSA-N 0.000 claims 1
- WCPQCNMXILWSCC-UHFFFAOYSA-N N-[2-(4-chlorophenoxy)ethyl]-1-[3-(4-chlorophenoxy)propanoyl]piperidine-4-carboxamide Chemical compound Clc1ccc(OCCNC(=O)C2CCN(CC2)C(=O)CCOc2ccc(Cl)cc2)cc1 WCPQCNMXILWSCC-UHFFFAOYSA-N 0.000 claims 1
- IJLSIMQFKDRPID-UHFFFAOYSA-N N-[2-(4-chlorophenoxy)ethyl]-1-[3-(4-chlorophenoxy)propyl]piperidine-4-carboxamide Chemical compound ClC1=CC=C(OCCNC(=O)C2CCN(CC2)CCCOC2=CC=C(C=C2)Cl)C=C1 IJLSIMQFKDRPID-UHFFFAOYSA-N 0.000 claims 1
- LBLCXIZMXJUKNN-UHFFFAOYSA-N N-[[1-[2-(4-chlorophenoxy)acetyl]piperidin-3-yl]methyl]-2-(6-chloropyridin-3-yl)oxyacetamide Chemical compound ClC1=CC=C(OCC(=O)N2CC(CCC2)CNC(COC=2C=NC(=CC=2)Cl)=O)C=C1 LBLCXIZMXJUKNN-UHFFFAOYSA-N 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 201000002154 Pterygium Diseases 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 208000002352 blister Diseases 0.000 claims 1
- 201000011143 bone giant cell tumor Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 claims 1
- 201000003714 breast lobular carcinoma Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 claims 1
- 201000004948 cheek mucosa cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 231100000782 microtubule inhibitor Toxicity 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000001491 myopia Diseases 0.000 claims 1
- 230000004379 myopia Effects 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 claims 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical group C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000002025 prostate sarcoma Diseases 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 230000003938 response to stress Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611019716 | 2016-06-08 | ||
| IN201611019716 | 2016-06-08 | ||
| PCT/IB2017/053372 WO2017212425A1 (en) | 2016-06-08 | 2017-06-07 | Chemical compounds as atf4 pathway inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521111A JP2019521111A (ja) | 2019-07-25 |
| JP2019521111A5 true JP2019521111A5 (enExample) | 2020-07-27 |
Family
ID=59227774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564345A Pending JP2019521111A (ja) | 2016-06-08 | 2017-06-07 | Ａｔｆ４経路阻害剤としての化学化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20190298705A1 (enExample) |
| EP (1) | EP3468960B1 (enExample) |
| JP (1) | JP2019521111A (enExample) |
| KR (1) | KR20190015748A (enExample) |
| CN (1) | CN109563071B (enExample) |
| AU (1) | AU2017279029A1 (enExample) |
| BR (1) | BR112018075598A2 (enExample) |
| CA (1) | CA3026982A1 (enExample) |
| ES (1) | ES2913929T3 (enExample) |
| RU (1) | RU2018145734A (enExample) |
| WO (1) | WO2017212425A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| CA3049010A1 (en) | 2017-01-06 | 2018-07-12 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| CR20200054A (es) | 2017-08-09 | 2020-03-21 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| HUE062446T2 (hu) | 2017-09-01 | 2023-11-28 | Denali Therapeutics Inc | Vegyületek, készítmények és eljárások |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| AU2018383675A1 (en) | 2017-12-13 | 2020-07-09 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| EP3768660A1 (en) * | 2018-03-23 | 2021-01-27 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| CA3094527A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| KR102224550B1 (ko) * | 2018-04-02 | 2021-03-09 | 울산대학교 산학협력단 | 신규한 에테르 화합물, 및 광 산화환원 촉매를 이용하여 활성화된 알켄 화합물로부터 에테르 화합물을 제조하는 방법 |
| MX2020013269A (es) * | 2018-06-05 | 2021-02-18 | Praxis Biotech LLC | Inhibidores de la vía de respuesta al estrés integrada. |
| EP3820843A1 (en) * | 2018-07-09 | 2021-05-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| TWI771621B (zh) | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| EP3923935A4 (en) | 2019-02-13 | 2022-10-26 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS AND METHODS |
| CA3137212A1 (en) * | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| IL287379B2 (en) * | 2019-04-23 | 2025-11-01 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| PE20220572A1 (es) * | 2019-04-30 | 2022-04-20 | Calico Life Sciences Llc | Moduladores de la via integrada del estres |
| CN114466654A (zh) * | 2019-06-12 | 2022-05-10 | 普拉西斯生物技术有限责任公司 | 整合应激反应通路调节剂 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| EP4096665A1 (en) * | 2020-01-28 | 2022-12-07 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| CA3165813A1 (en) | 2020-03-11 | 2021-09-16 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| CN116761803A (zh) * | 2020-10-22 | 2023-09-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| MX2023004626A (es) * | 2020-10-22 | 2023-05-23 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| AU2021363616B2 (en) * | 2020-10-22 | 2026-03-26 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| KR20230110509A (ko) * | 2020-10-22 | 2023-07-24 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| CN118019735A (zh) | 2021-08-18 | 2024-05-10 | 坎莫森特里克斯公司 | 作为ccr6抑制剂的芳基磺酰基化合物 |
| WO2023023532A2 (en) | 2021-08-18 | 2023-02-23 | Chemocentryx, Inc. | Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1353493A (en) | 1971-07-09 | 1974-05-15 | Beecham Group Ltd | Penicillins |
| DE3600390A1 (de) | 1986-01-09 | 1987-07-16 | Hoechst Ag | Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel |
| DK0520882T3 (da) | 1991-06-27 | 1995-12-11 | Synthelabo | Derivater af 2-aminopyrimidin-4-carboxamid, deres fremstilling og deres terapeutiske anvendelse |
| GB9319534D0 (en) | 1993-09-22 | 1993-11-10 | Boots Co Plc | Therapeutic agents |
| US5786360A (en) * | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| AU762345B2 (en) * | 1998-10-16 | 2003-06-26 | Asubio Pharma Co., Ltd. | Aminophenoxyacetic acid derivatives as neuroprotectants |
| EP1031564A1 (en) * | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
| SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| KR100853968B1 (ko) | 2000-04-13 | 2008-08-25 | 아스비오파마 가부시키가이샤 | 아미노페녹시아세트아미드 유도체 및 그를 함유하는약제학적 조성물 |
| ES2556946T3 (es) | 2000-12-21 | 2016-01-21 | Novartis Ag | Pirimidinaminas como moduladores de la angiogénesis |
| WO2003015717A2 (en) * | 2001-08-17 | 2003-02-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2002360561A1 (en) | 2001-12-11 | 2003-06-23 | Sepracor, Inc. | 4-substituted piperidines, and methods of use thereof |
| MY134200A (en) * | 2002-04-12 | 2007-11-30 | Kowa Co | Method for treating cancer |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| US7550599B2 (en) | 2003-02-26 | 2009-06-23 | Ciba Specialty Chemicals Corporation | Water compatible sterically hindered alkoxyamines and hydroxy substituted alkoxyamines |
| RU2006120084A (ru) * | 2003-11-10 | 2008-01-10 | Шеринг Акциенгезельшафт (De) | Бензилэфирамины, полезные как антагонисты ccr-5 |
| WO2005058885A2 (en) * | 2003-12-18 | 2005-06-30 | Glaxo Group Limited | Piperidine derivatives and their use as glycine transporter inhibitors |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US7897593B2 (en) | 2006-05-30 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| JP2010503676A (ja) | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 疼痛、糖尿病および脂質代謝の障害の治療 |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| TW200938203A (en) | 2007-12-17 | 2009-09-16 | Intervet Int Bv | Anthelmintic agents and their use |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2009151152A1 (en) * | 2008-06-11 | 2009-12-17 | Shionogi & Co., Ltd. | Oxycarbamoyl compounds and the use thereof |
| US20100048638A1 (en) * | 2008-07-01 | 2010-02-25 | Zacharon Pharmaceuticals, Inc. | Heparan sulfate inhibitors |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| CN101712679B (zh) | 2008-10-08 | 2013-04-10 | 中国科学院上海药物研究所 | 一种酰胺类化合物、其药物组合物及其制备方法和用途 |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP2013028538A (ja) * | 2009-11-13 | 2013-02-07 | Dainippon Sumitomo Pharma Co Ltd | 新規アミド誘導体 |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| US20140155419A1 (en) | 2011-07-29 | 2014-06-05 | Erkan Baloglu | Compounds and methods |
| EP2739358B1 (en) | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2013224302B2 (en) * | 2012-02-21 | 2017-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| EA026952B1 (ru) * | 2012-02-21 | 2017-06-30 | Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. | Применение 1h-индазол-3-карбоксамидных соединений в качестве ингибиторов гликогенсинтазы киназы 3-бета |
| WO2013170072A2 (en) | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Compounds for the treatment of neurological disorders |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| EP2956441A4 (en) | 2013-02-18 | 2016-11-02 | Scripps Research Inst | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL |
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| EP3116877A1 (en) * | 2014-03-11 | 2017-01-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Chemical compounds acting as perk inhibitors |
| WO2016055935A1 (en) * | 2014-10-06 | 2016-04-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist |
-
2017
- 2017-06-07 KR KR1020197000186A patent/KR20190015748A/ko not_active Withdrawn
- 2017-06-07 AU AU2017279029A patent/AU2017279029A1/en not_active Abandoned
- 2017-06-07 JP JP2018564345A patent/JP2019521111A/ja active Pending
- 2017-06-07 RU RU2018145734A patent/RU2018145734A/ru not_active Application Discontinuation
- 2017-06-07 ES ES17733530T patent/ES2913929T3/es active Active
- 2017-06-07 CN CN201780048778.1A patent/CN109563071B/zh active Active
- 2017-06-07 CA CA3026982A patent/CA3026982A1/en active Pending
- 2017-06-07 US US16/307,507 patent/US20190298705A1/en not_active Abandoned
- 2017-06-07 WO PCT/IB2017/053372 patent/WO2017212425A1/en not_active Ceased
- 2017-06-07 EP EP17733530.4A patent/EP3468960B1/en active Active
- 2017-06-07 BR BR112018075598-2A patent/BR112018075598A2/pt not_active IP Right Cessation
-
2020
- 2020-06-11 US US16/898,667 patent/US11547704B2/en active Active
-
2022
- 2022-12-06 US US18/075,664 patent/US20230165848A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521109A5 (enExample) | ||
| RU2018145734A (ru) | Химические соединения в качестве ингибиторов atf4 пути | |
| RU2018146946A (ru) | Химические соединения | |
| JP2021529814A5 (enExample) | ||
| JP7158382B2 (ja) | Ｃ－ｋｉｔ阻害剤としてのアミノチアゾール化合物 | |
| US10221139B2 (en) | Inhibitors of histone demethylases | |
| RU2018113430A (ru) | Производные l-фенилпирролидин-2-она в качестве ингибиторов perk | |
| ES2687985T3 (es) | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer colorrectal | |
| JP2021524842A5 (enExample) | ||
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2016053042A5 (enExample) | ||
| AU2018205204A1 (en) | Inhibitors of histone demethylases | |
| AU2018307743A1 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| JP2015502335A5 (enExample) | ||
| JP2013525458A5 (enExample) | ||
| JP2015533782A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2018517752A5 (enExample) | ||
| TW200410688A (en) | Therapeutics for diseases from vasoconstriction or vasodilatation | |
| JP2013534902A5 (enExample) | ||
| RU2014150338A (ru) | Соединение как ингибитор передачи сигналов wnt, его композиции и применение | |
| JP2017532360A5 (enExample) | ||
| TW202003487A (zh) | 經取代的２，２＇—聯嘧啶基化合物、其類似物及其使用方法 | |
| CA2905841A1 (en) | Quinazoline and naphthyridine derivatives useful in the treatment of fibrotic disorders | |
| CA2943824A1 (en) | Inhibitors of histone demethylases | |
| RU2015119218A (ru) | Комбинация |